Earnings History Data for Evolus, Inc. (EOLS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Evolus, Inc.

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
06-11-2024	AH		EOLS	Evolus, Inc.	1,040	-0.26	-0.17	-0.26	Evolus GAAP EPS of -$0.30 misses by $0.11, revenue of $61.1M misses by $2.3M [11/6/2024 4:43 PM]	14.36	-2.45 (-14.60%)	16.03	-0.78 (-4.64%)	7.74 - 17.82	1,639,600	420,000	2,455
Evolus GAAP EPS of -$0.30 misses by $0.11, revenue of $61.1M misses by $2.3M [11/6/2024 4:43 PM] Evolus Reports Third Quarter 2024 Results [2024-11-06 04:05PM]
31-07-2024	AH		EOLS	Evolus, Inc.	774.49	-0.14	-0.12	-0.28	Evolus reports mixed Q2 results; updates FY24 outlook [7/31/2024 5:17 PM]	14.02	1.60 (12.88%)	13.79	1.37 (11.03%)	7.44 - 15.43	1,283,258	340,000	3,224
Evolus reports mixed Q2 results; updates FY24 outlook [7/31/2024 5:17 PM]
07-05-2024	AH		EOLS	Evolus	827.00	-0.20	-0.07	0.00	Evolus GAAP EPS of -$0.22 in-line, revenue of $59.33M beats by $2.01M [5/7/2024 4:16 PM]	13.28	-0.14 (-1.08%)	13.47	0.05 (0.37%)	7.07 - 15.43	934,806	680,000	28,644
Evolus GAAP EPS of -$0.22 in-line, revenue of $59.33M beats by $2.01M [5/7/2024 4:16 PM]
07-03-2024	AH		EOLS	Evolus, Inc.	832.69	-0.20	-0.15	-0.19	Evolus GAAP EPS of -$0.21 in-line, revenue of $61M in-line [3/7/2024 4:26 PM]	14.10	-0.69 (-4.70%)	14.20	-0.59 (-3.99%)	7.07 - 15.43	1,387,479	640,000	1,718
Evolus GAAP EPS of -$0.21 in-line, revenue of $61M in-line [3/7/2024 4:26 PM]
07-11-2023	AH		EOLS	Evolus, Inc.	451.78	-0.26	-0.25	-0.36	Evolus GAAP EPS of -$0.30 misses by $0.01, revenue of $50M beats by $5.62M [11/7/2023 4:41 PM]	8.75	0.67 (8.29%)	9.15	1.07 (13.24%)	6.51 - 11.49	1,762,910	700,000	13,529
Evolus GAAP EPS of -$0.30 misses by $0.01, revenue of $50M beats by $5.62M [11/7/2023 4:41 PM]
02-08-2023	AH		EOLS	Evolus, Inc.	570.37	-0.28	-0.25	-0.42	Evolus GAAP EPS of -$0.32, revenue of $49.3M [8/2/2023 4:22 PM]	10.06	0.22 (2.24%)	10.10	0.26 (2.64%)	6.51 - 11.49	969,833	1,080,000	742
Evolus GAAP EPS of -$0.32, revenue of $49.3M [8/2/2023 4:22 PM]
08-03-2023	AH	4:05 PM ET (Mar 8)	EOLS	Evolus, Inc.	500.03	-0.19	-0.18	-0.33	Evolus GAAP EPS of -$0.23 misses by $0.02, revenue of $43.65M misses by $0.17M [3/8/2023 4:12 PM]	8.52	-0.34 (-3.84%)	8.85	-0.01 (-0.11%)	6.51 - 14.34	743,143	280,000	9,021
Evolus GAAP EPS of -$0.23 misses by $0.02, revenue of $43.65M misses by $0.17M [3/8/2023 4:12 PM]
08-11-2022	AH	4:05 PM ET (Nov 8)	EOLS	Evolus, Inc.	433.05	-0.36	-0.31	-0.35	Evolus GAAP EPS of -$0.36 in-line, revenue of $33.9M misses by $2.12M [11/8/2022 4:27 PM]	7.06	-0.72 (-9.25%)	7.78	0.0 (0.00%)	5.06 - 14.34	649,395	440,000	353
Evolus GAAP EPS of -$0.36 in-line, revenue of $33.9M misses by $2.12M [11/8/2022 4:27 PM] Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates [Nov-08-22 06:25PM] Evolus Reports Third Quarter 2022 Results and Provides Business Update [Nov-08-22 04:05PM]
02-08-2022	PM	8:00 AM ET (Aug 2)	EOLS	Evolus, Inc.	708.46	-0.42	-0.28	-0.31		10.76	-2.35 (-17.96%)	12.62	-0.49 (-3.74%)	5.06 - 14.34	2,102,707	510,000	4,839
Evolus Q2 2022 Earnings Preview [8/1/2022 1:11 PM] Evolus reports Q2 mixed earnings; reaffirms FY 2022 guidance [8/2/2022 8:22 AM] Evolus down 13% on 2022 guidance below estimates, wider-than-expected Q2 loss [8/2/2022 11:29 AM] Evolus Reports Second Quarter 2022 Results and Provides Business Update [Aug-02-22 08:05AM]
10-05-2022	AH	4:05 PM ET (May 10)	EOLS	Evolus, Inc.	616.50	-0.31	-0.46	0.16	Evolus GAAP EPS of -$0.31 beats by $0.12, revenue of $33.91M beats by $4.08M [5/10/2022 4:11 PM]	11.15	0.79 (7.63%)	9.85	-0.51 (-4.92%)	5.06 - 14.30	1,863,627	450,000	1,880
Evolus GAAP EPS of -$0.31 beats by $0.12, revenue of $33.91M beats by $4.08M [5/10/2022 4:11 PM] Evolus stock rises as Q1 revenue soars 177% Y/Y [5/11/2022 11:48 AM] Is Evolus (NASDAQ:EOLS) Using Too Much Debt? [May-10-22 11:26AM] Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates [May-10-22 06:15PM] Evolus Reports First Quarter 2022 Results and Provides Business Update [May-10-22 04:05PM] Evolus to Participate in the H.C. Wainwright Global Investment Conference [May-11-22 08:45AM]
03-03-2022	AH	4:05 PM ET (Mar 3)	EOLS	Evolus, Inc.	508.53	-0.33	-0.41	-0.81	Evolus GAAP EPS of -$0.33 beats by $0.07, revenue of $34.7M misses by $0.07M [3/3/2022 4:14 PM]	9.45	0.43 (4.77%)	8.95	-0.07 (-0.78%)	5.06 - 17.38	544,474	380,000	358
Evolus GAAP EPS of -$0.33 beats by $0.07, revenue of $34.7M misses by $0.07M [3/3/2022 4:14 PM] Evolus Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update [Mar-03-22 04:05PM] Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail [Mar-03-22 04:05PM] Evolus, Inc. (EOLS) Reports Q4 Loss, Misses Revenue Estimates [Mar-03-22 05:55PM]
02-11-2021	PM	7:00 AM ET (Nov 2)	EOLS	Evolus, Inc.	416.42	-0.35	-0.38	-0.34	Evolus EPS beats by $0.01, beats on revenue [11/2/2021 8:17 AM]	8.00	-0.38 (-4.53%)	8.00	0.0 (0.00%)	2.94 - 17.38	594,532	380,000	8,563
Evolus Q3 2021 Earnings Preview [11/1/2021 12:25 PM] Evolus EPS beats by $0.01, beats on revenue [11/2/2021 8:17 AM] Evolus begins phase 2 program for extended duration extra strength dose of Jeuveau [11/2/2021 8:40 AM] Evolus Announces Appointment of Jessica Novak as Senior Vice President, Human Resources [Nov-01-21 04:10PM] Evolus Reports Third Quarter 2021 Results and Provides Business Update [Nov-02-21 08:03AM] Evolus Initiates Phase II Program with Extra Strength Dose for Extended Duration [Nov-02-21 08:01AM] Evolus, Inc. (EOLS) Reports Q3 Loss, Lags Revenue Estimates [Nov-02-21 09:35AM]
04-08-2021	AH	4:05 PM ET (Aug 4)	EOLS	Evolus, Inc.	585.58	-0.31	-0.30	-0.63	Evolus EPS misses by $0.02, beats on revenue [8/4/2021 4:33 PM]	10.52	-0.88 (-7.72%)	10.49	-0.91 (-7.98%)	2.85 - 17.38	753,195	400,000	9,156
Evolus EPS misses by $0.02, beats on revenue [8/4/2021 4:33 PM] Evolus Reports Second Quarter 2021 Results and Provides Business Update [Aug-04-21 04:05PM] Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates [Aug-04-21 06:05PM]
12-05-2021	AH	4:05 PM ET (May 12)	EOLS	Evolus, Inc.	481.98	0.16	-0.58	-0.59	Evolus EPS beats by $0.57, beats on revenue [5/12/2021 4:10 PM]	8.61	0.19 (2.26%)	8.66	0.24 (2.85%)	2.85 - 17.38	1,165,432	820,000	14,491
Evolus EPS beats by $0.57, beats on revenue [5/12/2021 4:10 PM] Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store? [May-11-21 12:18PM] Aesthetic Surgery Journal Publishes Long Term Safety and Efficacy Data of Jeuveau® for the Treatment of Moderate to Severe Frown Lines [May-12-21 09:00AM] Repeat Doses Of Evolus' Frown Lines Treatment Are Safe, With Decreasing Rates Of Adverse Events [May-12-21 10:33AM] Evolus, Inc. to Host Earnings Call [May-12-21 02:30PM] Evolus Reports First Quarter 2021 Results and Provides Business Update [May-12-21 04:05PM]
24-03-2021	AH	4:05 PM ET (Mar 24)	EOLS	Evolus, Inc.	468.44	-0.81	-0.33	-0.47	Evolus EPS misses by $2.94, beats on revenue [3/24/2021 4:12 PM]	12.79	-3.72 (-22.53%)	14.40	-2.11 (-12.78%)	2.85 - 17.38	2,729,342	1,160,000	33,397
Evolus EPS misses by $2.94, beats on revenue [3/24/2021 4:12 PM] Evolus shares drop 10% as Q4 net loss widened amid litigation headwinds [3/25/2021 9:06 AM] Evolus to Report Fourth Quarter and Year End 2020 Results and Provide Business Update [Mar-23-21 09:21AM] Evolus Strengthens Balance Sheet Through a $25.5 Million Cash Infusion and Elimination of $127.4 Million of Debt and Milestone Payments [Mar-23-21 09:17AM] Daewoong Pharmaceutical Injects More Liquidity In Evolus [Mar-23-21 01:52PM] Evolus, Inc. (EOLS) Reports Q4 Loss, Lags Revenue Estimates [Mar-24-21 05:35PM] Evolus Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update [Mar-24-21 04:05PM] Evolus Slips 10% On Wider-Than-Expected 4Q Loss [Mar-25-21 02:45AM]
29-10-2020	AH		EOLS	Evolus, Inc.	110.00	-0.34	-0.35	0.00		3.02	0.10 (3.38%)	2.95	0.03 (1.03%)	2.85 - 17.39	464,264	422,235	7,451

10-08-2020	AH	4:00 PM ET (Aug 10)	EOLS	Evolus, Inc.	115.35	-0.63	-0.84	-1.37	Evolus EPS beats by $0.16, beats on revenue [8/10/2020 4:14 PM]	3.81	0.10 (2.70%)	3.90	0.19 (5.12%)	3.00 - 19.00	722,240	466,256	4,915